Wisevoter
World

Asundexian Cuts Stroke Recurrence Without Added Bleeding

A Bayer-sponsored MRI substudy of the OCEANIC-STROKE trial found the drug reduced recurrent ischemic stroke across baseline infarct patterns.

Updated on Nov. 3, 2026 in Stroke

Bold flat-color editorial illustration of a smooth capsule beside a layered brain-tissue cross-section in deep teal, cream, and oxblood.
Bayer's asundexian cut recurrent ischemic stroke without adding major bleeding, regardless of baseline MRI infarct pattern, a substudy presented in Seoul showed. AI Illustration. Upload story photo >

Live Poll

Would you feel comfortable taking a new stroke-prevention pill if it lowered stroke risk without more bleeding?

Bayer's asundexian reduced recurrent ischemic stroke without increasing major bleeding, regardless of baseline MRI infarct pattern, according to a substudy presented at the World Stroke Congress 2026 in Seoul, South Korea. The analysis was presented by Raed Joundi of McMaster University.

Why it matters

Stroke patients with different infarct patterns on imaging may respond to treatment differently, so showing a consistent benefit across patterns helps clinicians understand who may be suited to therapy. The substudy was designed to better characterize patients by imaging and other markers to see whether these factors affect treatment effect.

In the MRI substudy, ischemic stroke occurred in 8.2% of asundexian patients versus 12.1% of placebo patients (csHR 0.67; 95% CI, 0.46-0.98). Only 2 intracerebral hemorrhages occurred per group, and no significant interaction with infarct pattern was found.

The players

Bayer

Bayer is a multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, and the sponsor of the asundexian development program.

Raed Joundi

Raed Joundi is a researcher at McMaster University who presented the OCEANIC-STROKE MRI substudy at the World Stroke Congress 2026.

The details

OCEANIC-STROKE enrolled 12,327 patients with noncardioembolic ischemic stroke or TIA, randomized 6,162 to asundexian and 6,165 to placebo, all on antiplatelet therapy. The substudy grouped patients by baseline MRI infarct pattern, including subcortical infarcts of 15 mm or greater and cortical infarcts, and was presented in Seoul.

Timeline

  1. October 21-23, 2026: World Stroke Congress 2026 presentation in Seoul, South Korea.

  2. Over 19 months of trial follow-up, ischemic stroke incidence was measured.

  3. November 12, 2025: The OCEANIC-STROKE ClinicalTrials.gov record was last updated.

Health Landscape

The OCEANIC-STROKE program is Bayer's phase 3 effort to test a factor XIa inhibitor in noncardioembolic stroke, an area where preventing recurrence without raising bleeding risk has long been difficult. This MRI substudy extends that program by checking whether the benefit holds across infarct patterns defined by imaging.

If asundexian is approved, stroke patients taking it alongside antiplatelet therapy could see reduced recurrence risk without a rise in major bleeding in the trial population. The benefit appeared consistent across imaging-defined infarct patterns, though approval and availability remain separate questions.

The takeaway

Stroke prevention trials increasingly examine whether benefits hold across specific imaging subtypes rather than only in overall populations. Readers interested in stroke risk should discuss antiplatelet and anticoagulation options with their own clinicians.

Further reading

For background on the condition at the center of this research, see the Stroke section.

More information

Review the trial details in the OCEANIC-STROKE ClinicalTrials.gov registry record on the National Library of Medicine portal.

Source note: This article includes information reported by Hcplive.

Live Poll

Would you feel comfortable taking a new stroke-prevention pill if it lowered stroke risk without more bleeding?